Sentence examples for molecular diagnostics based from inspiring English sources

Recent advances in the understanding of the molecular basis of cancer and the development of molecular diagnostics based on this knowledge have done much to progress the fields of oncology and pathology.

Molecular diagnostics based on nucleic acids use polymerase chain reaction (PCR) to vastly increase the number of nucleic acid molecules and amplify the target.

In addition, molecular diagnostics based on analysis of biopsied or surgically resected tumor tissue is hampered by sampling error.

In the past decades the rapid growth of molecular diagnostics (based on either traditional PCR or isothermal amplification technologies) meet the demand for fast and accurate testing.

Molecular diagnostics based on the polymerase chain reaction (PCR) offer rapid and sensitive means for detecting infectious disease, but prohibitive costs have impeded their use in resource-limited settings where such diseases are endemic.

One hundred and two cases with tumour-adjacent margins, considered to be clear margins by microscopy, were examined using carefully optimised molecular diagnostics based on detection of the TP53 and Ly-6D markers.

Alanyl-peptide nucleic acid (alanyl-PNA)/DNA chimeras are oligomers envisaged to be beneficial in efficient DNA diagnostics based on an improved molecular beacon concept.

The issues related to inefficiency of current infectious disease diagnostics based on culture and simple molecular assays remain a serious challenge.

In practice, the optimal development of diagnostics based on liquid biopsies defined here as biofluids used for molecular diagnostics will require next-level interdisciplinary action of clinical chemists, clinical geneticists, microbiologists, and (molecular) pathologists, among others.

The validation results confirm that the molecular profile can accurately determine samples with a sufficient tumour percentage for microarray diagnostics based on transcriptional analysis of 13 identified genes.

Clinical laboratories are naturally striving to implement molecular diagnostic tests based on genomic methods such as massively parallel sequencing in order to provide genetic diagnosis at the genome scale, while leveraging the parallel processing and nanoscale architecture inherent in these technologies to consolidate costs and maintain turnaround times.